- Predictive presymptomatic testing is a type of genetic testing used to identify individuals at risk of developing certain genetic conditions before symptoms appear, enabling early intervention or preventive care
- The Predictive Presymptomatic Testing Market is witnessing rapid growth driven by advancements in genetic testing technologies, such as next-generation sequencing, which allows for more accurate and efficient identification of genetic predispositions
- For instance, companies such as Illumina are revolutionizing the field with their cutting-edge sequencing platforms used in clinical settings
- With the increasing availability of genetic testing services through platforms such as 23andMe and AncestryDNA, more individuals are opting for predictive testing to understand their risks for conditions such as Alzheimer’s and certain types of cancer
- For instance, 23andMe offers genetic testing that helps users identify whether they carry genetic variants linked to conditions such as Parkinson’s disease
- The rise of telemedicine has made genetic testing more accessible, as companies such as Invitae and Myriad Genetics offer at-home testing kits, enabling people to consult healthcare professionals remotely for genetic counselling and test results
- For instance, Invitae, provides genetic testing for hereditary cancers, offering remote consultations to help patients understand their results
- Personalized medicine is a key trend in the market, as predictive testing allows doctors to create tailored treatment plans based on an individual’s genetic makeup, improving the effectiveness of interventions and care strategies
- For instance, genetic testing is used in oncology to identify specific genetic mutations in cancers, which helps doctors recommend targeted therapies such as those used in treating breast cancer with HER2-positive mutations
- The market is also expanding as awareness grows about the benefits of early detection, with organizations such as the American Cancer Society promoting the importance of genetic testing for individuals with a family history of cancer. In 2020, the ACS updated its guidelines, encouraging genetic testing for individuals with a higher risk of hereditary cancers such as those with BRCA mutations
